论文部分内容阅读
目的观察雷替曲塞注射剂联合奥沙利铂注射剂治疗晚期胃癌的临床疗效和安全性。方法将44例晚期胃癌患者随机分为对照组22例和试验组22例。对照组予以第1天奥沙利铂130 mg·m~(-2),静脉滴注3 h+第1~5天亚叶酸钙200 mg·m~(-2),静脉滴注+第1~5天氟尿嘧啶375 mg·m~(-2),静脉滴注;试验组予以第1天雷替曲塞3 mg·m~(-2),静脉滴注15 min+第1天奥沙利铂130 mg·m~(-2),静脉滴注3 h。2组患者1个周期均为3周,共治疗2个周期。比较2组患者的临床疗效、中位无疾病进展时间和药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为59.09%(13/22例)和31.82%(7/22例),中位无疾病进展时间分别为7.1和5.6个月,差异均有统计学意义(均P<0.05)。2组患者的药物不良反应主要为粒细胞减少和恶心呕吐。试验组和对照组的血液学毒性发生率分别为18.18%和13.64%,消化道反应发生率分别为4.55%和9.09%,差异均无统计学意义(均P>0.05)。结论雷替曲塞注射剂联合奥沙利铂注射剂治疗晚期胃癌的临床疗效确切,且不增加药物不良反应的发生率。
Objective To observe the clinical efficacy and safety of raltitrexed injection combined with oxaliplatin injection in the treatment of advanced gastric cancer. Methods Forty-four patients with advanced gastric cancer were randomly divided into control group (22 cases) and experimental group (22 cases). The control group was given oxaliplatin 130 mg · m -2 on the first day, the levofloxacin 200 mg · m -2 on the 1st ~ 5th day after the intravenous drip 3 h, the intravenous drip + 5 days of fluorouracil 375 mg · m -2, intravenous drip; test group were given on the first day of raltitrexed 3 mg · m -2, intravenous infusion of 15 min + on the first day oxaliplatin 130 mg · m ~ (-2), intravenous infusion of 3 h. One cycle of two groups of patients were 3 weeks, a total of 2 cycles. The clinical efficacy, median progression-free time and adverse drug reactions were compared between the two groups. Results After treatment, the total effective rates of the experimental group and the control group were 59.09% (13/22 cases) and 31.82% (7/22 cases), respectively, and the median progression-free time was 7.1 and 5.6 months respectively Statistical significance (all P <0.05). Adverse drug reactions in 2 groups were mainly neutropenia and nausea and vomiting. The incidences of hematological toxicity in trial group and control group were 18.18% and 13.64% respectively, and the incidences of digestive tract reactions were 4.55% and 9.09%, respectively, with no significant difference (all P> 0.05). Conclusion Raltitrexed injection combined with oxaliplatin injection in the treatment of advanced gastric cancer is effective and does not increase the incidence of adverse drug reactions.